- Home
- RPRX vs SNN Comparison
RPRX vs SNN Comparison
Compare RPRX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- SNN
- Stock Information
- Founded
- RPRX 1996
- SNN 1856
- Country
- RPRX United States
- SNN United Kingdom
- Employees
- RPRX N/A
- SNN N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- RPRX Health Care
- SNN Health Care
- Exchange
- RPRX Nasdaq
- SNN Nasdaq
- Market Cap
- RPRX 13.9B
- SNN 12.7B
- IPO Year
- RPRX 2020
- SNN 1999
- Fundamental
- Price
- RPRX $33.58
- SNN $30.07
- Analyst Decision
- RPRX Strong Buy
- SNN Hold
- Analyst Count
- RPRX 3
- SNN 3
- Target Price
- RPRX $47.33
- SNN $27.50
- AVG Volume (30 Days)
- RPRX 5.5M
- SNN 598.8K
- Earning Date
- RPRX 05-08-2025
- SNN 07-31-2025
- Dividend Yield
- RPRX 2.62%
- SNN 2.49%
- EPS Growth
- RPRX 37.60
- SNN 56.15
- EPS
- RPRX 2.45
- SNN 0.47
- Revenue
- RPRX $2,263,845,000.00
- SNN $5,810,000,000.00
- Revenue This Year
- RPRX $29.35
- SNN $6.87
- Revenue Next Year
- RPRX $7.58
- SNN $5.19
- P/E Ratio
- RPRX $13.70
- SNN $32.08
- Revenue Growth
- RPRX 1.13
- SNN 4.70
- 52 Week Low
- RPRX $24.05
- SNN $23.69
- 52 Week High
- RPRX $34.32
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- RPRX 56.69
- SNN 65.26
- Support Level
- RPRX $33.37
- SNN $29.84
- Resistance Level
- RPRX $33.97
- SNN $29.27
- Average True Range (ATR)
- RPRX 0.53
- SNN 0.34
- MACD
- RPRX 0.05
- SNN 0.08
- Stochastic Oscillator
- RPRX 76.06
- SNN 84.56
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.